Lantheus Holdings Inc
NASDAQ:LNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lantheus Holdings Inc
Other Equity
Lantheus Holdings Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Other Equity
-$1.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Figs Inc
NYSE:FIGS
|
Other Equity
$195.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Other Equity
-$34.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Other Equity
-$25.1m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-2%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Other Equity
$75.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Other Equity
-$3.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
See Also
What is Lantheus Holdings Inc's Other Equity?
Other Equity
-1.3m
USD
Based on the financial report for Dec 31, 2025, Lantheus Holdings Inc's Other Equity amounts to -1.3m USD.
What is Lantheus Holdings Inc's Other Equity growth rate?
Other Equity CAGR 10Y
4%
Over the last year, the Other Equity growth was 19%.